Physician profile
John H Mcvey
NPI 1669477329
$1,625.83
in general payments reported to CMS, 2019-2025
15 companies · $322 in 2025
The $322 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $166 · 2021: $329 · 2022: $309 · 2023: $121 · 2024: $379 · 2025: $322.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $822.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $821.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $657.71 | 2019-2025 | Total30, Clareon Panoptix Pro, Rocklatan |
| Abbvie INC. | $222.35 | 2022-2025 | |
| Amgen INC. | $173.44 | 2024-2025 | Tepezza |
| Apellis Pharmaceuticals, INC. | $125.00 | 2024 | Syfovre |
| Rxsight INC | $116.11 | 2022-2025 | Rxsight Contact Lens, Light Adjustable Lens (Lal), Rxsight Injector Cartridge |
| Horizon Therapeutics Plc | $79.84 | 2022-2023 | Tepezza |
| Mallinckrodt Hospital Products INC. | $64.13 | 2025 | Acthar |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $38.48 | 2019 | |
| Aerie Pharmaceuticals, INC. | $38.17 | 2021 | |
| Kala Pharmaceuticals, INC. | $26.40 | 2021-2022 | |
| Tarsus Pharmaceuticals, INC. | $23.61 | 2024 | Xdemvy |
| Thea Pharma INC. | $20.63 | 2024 | Iyuzeh |
| Allergan, INC. | $14.04 | 2021 | |
| Bausch & Lomb Americas INC. | $13.97 | 2024 | Vyzulta, Miebo |
| Travere Therapeutics, INC. | $11.95 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Mcvey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.